Candel Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Kendrick St Ste 450, Needham, Massac...Phone Number
(617) 916-5445Website
www.candeltx.comRevenue
-Stock Symbol
CADLIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Candel Therapeutics
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained anti-cancer effect based on a highly individualized T cell response against the injected tumor and uninjected metastases, and has the potential to change disease outcomes across a variety of indications.Explore more
Candel Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Candel Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Candel Therapeutics
Funding: Get notified immidiatlly once Candel Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Candel Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Candel Therapeutics recently announced quarterly report
Product Launch: Get notified when Candel Therapeutics launches new products
Check out if Candel Therapeutics is spiking on competitors!
Candel Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Candel Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Candel Therapeutics
Find 3 more new buyers
Compare Similar Companies to Candel Therapeutics
Compare insights from companies similar to Candel Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$123.9M
51-200
Public
$462.1M
1994
TC
Tracy ClementeChief People Officer & Chief Human Resources Officer
Company Profile Activity
Activity Insights
Candel Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Candel Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Candel Therapeutics.
Candel Therapeutics financials insights
Gather financial insights about Candel Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$14.2M
2019
Series B
$28.7M
Series C
$22.5M
2025
Debt
$130M
Candel Therapeutics Tech Stack
A closer look at the technologies used by Candel Therapeutics
Most Recent Scoops
Open Position
Person-Based
Medical Research
Person-Based
Earnings, Medical Research, Pharmaceuticals, Finance
Open Position
Person-Based
Pharmaceuticals, Finance, Investor Relations
Candel Therapeutics News & Media
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company’s common stock, with a perCandel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer Transcript
Candel Therapeutics, Inc. (CADL) Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, 2026...Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
NEEDHAM, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced new results from extended follow-up of its randomized, double-blind, placebo-controlled pivotal phase 3 trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in intermediate- to high-risk localized prostate cancer. TCandel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the first quarter ended March 31, 2026, and provided a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Candel Therapeutics
Sign Up For FreeTo access detailed company insights
Candel Therapeutics is developing viral immunotherapies that are designed to cause in situ vaccination against the unique antigens and neoantigens presented when tumor cells lyse and stimulate activation of both innate and adaptive immune mechanisms. The patient and tumor-specific memory response has been shown to produce a systemic and sustained a... Read More
